Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the feasibility and tolerability of neo-adjuvant/adjuvant Darovasertib on uveal melanoma patients. Who is it for? Patients may be eligible to join this study with high-risk uveal melanoma and planned to undergo enucleation Study details: Eligible patients will undergo up to 4 weeks of treatment with Darovasertib (300mg, twice a day as a starting dose) after fulfilling inclusion/exclusion criteria and consent. Select patients will undergo adjuvant treatment for 6 months based on their initial response. It is hoped that this research will provide insight into the safety and tolerability of Darovasertib. Furthermore, it aims to document the pharmacodynamic and pharmacokinectic effects of Darovasertib on uveal melanoma patients.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05187884
Study type Interventional
Source St Vincent's Hospital, Sydney
Contact Anthony Joshua, FRACP, MBBS, PhD
Phone +61 293555655
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date January 21, 2022
Completion date November 1, 2024

See also
  Status Clinical Trial Phase
Completed NCT01200238 - STA-9090(Ganetespib) in Metastatic Ocular Melanoma Phase 2
Active, not recruiting NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases Phase 1
Completed NCT01355120 - THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Phase 2
Recruiting NCT02909517 - The Role of Inflammation in Ocular Tumours
Withdrawn NCT00621439 - Investigative Trial of Interferon Alpha-2b To Shrink Cancer of the Eye N/A
Terminated NCT00346372 - Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy
Not yet recruiting NCT03172299 - Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Phase 3
Completed NCT01893099 - Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Active, not recruiting NCT03528408 - Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma Phase 2
Not yet recruiting NCT01930968 - Definity for Ultrasound of Intraocular Tumors
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Recruiting NCT00168870 - Study of Metastatic Ocular Melanoma Phase 2
Active, not recruiting NCT02519322 - Neoadjuvant and Adjuvant Checkpoint Blockade Phase 2
Recruiting NCT04417530 - Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2
Completed NCT02129075 - A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma Phase 2
No longer available NCT01728051 - Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver N/A